Barts Health NHS Trust has appointed Professor Sir Mark Caulfield as a non-executive director for the organisation.
He replaces the outgoing Professor Steve Thornton, who is a consultant obstetrician and Vice-President for Health at Queen Mary University of London (QMUL).
Sir Mark will take over his role as the nominated representative for QMUL on Barts’ trust board, with Professor Thornton set to join UCL Partners on secondment, as Interim Managing Director.
The new Non-Executive Director specialises in genomic medicine research, and has also recently been appointed as Chief Executive of Barts Life Sciences, which is the trust’s collaboration on “cutting-edge clinical innovation” with its “academic partners and neighbours” at QMUL.
Sir Mark, who trained in clinical pharmacology at St Bartholomew’s Hospital, has also previously held the position of Chief Scientist at Genomics England and was knighted for his work on the 100,000 Genomes Project – which involved the sequencing of genomes from around 85,000 NHS patients affected by a rare disease, or cancer – in 2019.
Barts describes its new appointee as “a leading force in the creation of the Barts Heart Centre”, and praises his work at QMUL, where it says Sir Mark has, “made substantial contributions to the discovery of genes related to cardiovascular health, cancer and rare diseases.”
Despite his new post, Sir Mark will remain as Professor of Clinical Pharmacology in the William Harvey Research Institute at QMUL.
